Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%
Please Click the Issue to Download
Introduction
This resource provides insights and guidance by a thought leader into frequently asked questions on the open-label, phase 3, Checkmate 227 study evaluating the use of 1L nivolumab in combination with low-dose ipilimumab in patients with metastatic NSCLC and PD-L1 ≥1%. It was recently updated to include 4-year extended follow-up data for the Checkmate 227 study, with a median follow-up of 54.8 months, presented by researchers at the American Society of Clinical Oncology 2021 annual meeting.
